Nigerian pharmaceutical industry: Big steps, setbacks, prospects

11 total views, no views today

Nigeria’s drug makers have made big steps in recent times.

In 2018, an Anambra State-based drug maker, Juhel Nigeria, unveiled a new Oxytocin injection for pregnant women, the first of its kind in Africa.

Juhel’s injection, unveiled in Lagos in May, was manufactured in collaboration with the United States Pharmacopeia (USP). It has the capacity to reduce after-birth bleeding and maternal deaths, estimated at 58, 000 each year. The drug was hitherto imported outside Africa but is now locally manufactured in Awka, Anambra State, Ifeanyi Okoye, CEO of Juhel Nigeria Limited, said.

“We have the capacity to produce enough Oxytocin that will serve the rest of sub-Saharan Africa,” Okoye said.

Fidson Healthcare is a stand-out performer that no one can afford to ignore in the pharmaceutical space. The drug maker has an ultra-modern plant in Ogun State that matches what is seen in India, Brazil and the United States—countries well-known for drug manufacture.

The new manufacturing facility is one of the five facilities shortlisted for World Health Organisation (WHO) certification in Nigeria. It is an ultra-modern facility with high-tech machinery for manufacturing pharmaceutical products, in compliance with global standards and WHO certification. It is equipped with six production lines – tablets, capsules, liquids, cream and ointments, dry powder and intravenous fluids to meet the needs of the Nigerian and West African markets.

It once partnered United States firms, Immune Therapeutics, GB Pharma and American Hospitals & Resort (AHAR), for the marketing and distribution of Lodonal, a patent-protected product that is indicated for the management of patients with immune-compromising diseases.

Fidson today is owned by foreign investors to the tune of 25 percent.

It has pumped between N20 and N25 billion into its facilities in Lagos and Ogun states, said Fidelis Akhagboso Ayebae, founder and chief … Read More...